Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Authors: Jones, R., Hickish, T. et al.
Journal: ANNALS OF ONCOLOGY
Volume: 31
Pages: S1151
eISSN: 1569-8041
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2020.08.2248
Source: Web of Science (Lite)